US Supreme Court rejects 'Pharma Bro' Martin Shkreli's appeal of penalties
Shkreli appeal did not contest lifetime drug industry ban
Antitrust case was brought by federal agency, seven states
Adds background in paragraphs 3-13
By Jonathan Stempel
Oct 7 (Reuters) -The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 million financial penalty imposed by a judge after he raised a lifesaving drug's price by more than 4,000%.
The justices turned away Shkreli's appeal of a lower court's decision upholding the penalty, equal to the profits he and one of his former companies made by raising the price of the drug Daraprim in 2015. Shkreli, then in his early 30s, was given the nickname "Pharma Bro" in the media. His penalty had been imposed in 2022 by U.S. District Judge Denise Cote in Manhattan.
Shkreli's appeal did not challenge a lifetime ban from the drug industry also imposed by Cote.
The judge cited Shkreli's "particularly heartless and coercive" tactics in monopolizing Daraprim and keeping generic rivals off the market. Cote imposed the sanctions in a civil antitrust case brought by the U.S. Federal Trade Commission, along with the states of New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia.
Shkreli asked the Supreme Court to review a January decision by 2nd U.S. Circuit Court of Appeals in Manhattan, which upheld the $64.6 million penalty as well as the industry ban.
Now 41, Shkreli gained notoriety when, as chief executive of Turing Pharmaceuticals, he raised Daraprim's price overnight to $750 per tablet from $17.50.
Daraprim is used to treat a parasitic infection called toxoplasmosis, including in people with AIDS.
Shkreli later served more than four years in prison after being convicted in 2017 for defrauding investors in two hedge funds and scheming to defraud investors in another drugmaker.
He argued in his Supreme Court appeal that he should not owe the entire $64.6 million.
Shkreli said it was unfair to give up profits he never personally received or controlled, and that two other federal appeals courts have limited the liability of defendants in personal gains.
The states countered that the appeal to the Supreme Court was a "poor vehicle" to review Shkreli's disgorged profits because lower courts never addressed the issue.
Since his May 2022 release from prison, Shkreli has worked as a software developer and as a consultant for a law office.
He has separately been sued by the digital art collective PleasrDAO for having allegedly streamed a one-of-a-kind album by the hip-hop group Wu-Tang Clan. PleasrDAO bought the album after the U.S. government seized it from Shkreli in his criminal case.
Reporting by Jonathan Stempel in New York; Editing by Will Dunham
Dernières actualités
Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.
Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.
Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.
